资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医迅达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#滤泡性淋巴瘤#
69篇内容 | 2013人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=5bd36658e94, topicName=滤泡性淋巴瘤, introduction=滤泡性淋巴瘤, content=null, image=null, comments=69, allHits=2013, url=https://h5.medsci.cn/topic?id=66587, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=10568, tagList=[TagDto(tagId=10568, tagName=滤泡性淋巴瘤)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1278792, encodeId=a0ef12e879210, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet Haematol:R-CHOP作为新确诊晚期滤泡性淋巴瘤患者一线治疗怎么样?, objectType=article, longId=155657, objectId=637315565e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=637315565e43, replyNumber=0, likeNumber=32, createdTime=2018-12-14, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=637315565e43, moduleTitle=Lancet Haematol:R-CHOP作为新确诊晚期滤泡性淋巴瘤患者一线治疗怎么样?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=637315565e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278791, encodeId=7bbf12e879189, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=JCO:利妥昔单抗时代滤泡性淋巴瘤死亡原因:队列汇总分析, objectType=article, longId=154619, objectId=34e2154619e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34e2154619e9, replyNumber=0, likeNumber=37, createdTime=2018-11-30, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34e2154619e9, moduleTitle=JCO:利妥昔单抗时代滤泡性淋巴瘤死亡原因:队列汇总分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34e2154619e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278790, encodeId=495812e879025, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:以PET-CT分层可提高滤泡性淋巴瘤患者的放射治疗效果, objectType=article, longId=153807, objectId=a21f15380eae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a21f15380eae, replyNumber=0, likeNumber=46, createdTime=2018-11-19, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a21f15380eae, moduleTitle=Blood:以PET-CT分层可提高滤泡性淋巴瘤患者的放射治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a21f15380eae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278789, encodeId=f2b512e878994, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:基因组变异情况可用于预测滤泡性淋巴瘤患者的预后, objectType=article, longId=153806, objectId=340d15380698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=340d15380698, replyNumber=0, likeNumber=41, createdTime=2018-11-19, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=340d15380698, moduleTitle=Blood:基因组变异情况可用于预测滤泡性淋巴瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=340d15380698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278788, encodeId=bef012e878865, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet oncol:滤泡性淋巴瘤患者经一线免疫化疗后,以PET评估缓解情况的效果优于增强CT, objectType=article, longId=150640, objectId=75151506400f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75151506400f, replyNumber=0, likeNumber=38, createdTime=2018-10-11, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75151506400f, moduleTitle=Lancet oncol:滤泡性淋巴瘤患者经一线免疫化疗后,以PET评估缓解情况的效果优于增强CT, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75151506400f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278787, encodeId=d5a312e87879a, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=N Engl J Med:晚期滤泡性淋巴瘤:利妥昔单抗+来那度胺vs利妥昔单抗+化疗, objectType=article, longId=149892, objectId=952414989202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=952414989202, replyNumber=0, likeNumber=44, createdTime=2018-09-30, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=952414989202, moduleTitle=N Engl J Med:晚期滤泡性淋巴瘤:利妥昔单抗+来那度胺vs利妥昔单抗+化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=952414989202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278786, encodeId=48db12e87868b, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:MiR-150下调通过上调FOXP1促进滤泡性淋巴瘤向高级别淋巴瘤转化, objectType=article, longId=149072, objectId=da1a1490e2ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da1a1490e2ca, replyNumber=0, likeNumber=44, createdTime=2018-09-20, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da1a1490e2ca, moduleTitle=Blood:MiR-150下调通过上调FOXP1促进滤泡性淋巴瘤向高级别淋巴瘤转化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da1a1490e2ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278785, encodeId=5e0112e8785d2, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=2018 多学科意见书:慢性淋巴细胞白血病和滤泡性淋巴瘤应用艾代拉利司治疗相关不良事件的管理, objectType=article, longId=148933, objectId=8f99148933a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f99148933a1, replyNumber=0, likeNumber=20, createdTime=2018-09-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f99148933a1, moduleTitle=2018 多学科意见书:慢性淋巴细胞白血病和滤泡性淋巴瘤应用艾代拉利司治疗相关不良事件的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f99148933a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278784, encodeId=cd6212e8784cc, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=NEJM:来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤, objectType=article, longId=148651, objectId=82c314865156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c314865156, replyNumber=0, likeNumber=43, createdTime=2018-09-13, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c314865156, moduleTitle=NEJM:来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c314865156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278783, encodeId=3d8912e8783bf, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:十二指肠型滤泡性淋巴瘤, objectType=article, longId=147150, objectId=2be914e15021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be914e15021, replyNumber=0, likeNumber=46, createdTime=2018-08-23, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be914e15021, moduleTitle=Blood:十二指肠型滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be914e15021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278782, encodeId=0a9412e87827f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=J Gastroen Hepatol:无症状且肿瘤负担较低的肠滤泡性淋巴瘤的治疗方法选择, objectType=article, longId=145683, objectId=3a2914568355, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a2914568355, replyNumber=0, likeNumber=35, createdTime=2018-08-03, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a2914568355, moduleTitle=J Gastroen Hepatol:无症状且肿瘤负担较低的肠滤泡性淋巴瘤的治疗方法选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a2914568355)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278781, encodeId=14a412e878111, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet haemat:利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险, objectType=article, longId=142572, objectId=f2021425e29a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2021425e29a, replyNumber=0, likeNumber=38, createdTime=2018-07-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2021425e29a, moduleTitle=Lancet haemat:利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2021425e29a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278780, encodeId=9b0312e878032, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet Oncol:基因表达谱数据再建新功:精准判断部分滤泡性淋巴瘤患者的预后, objectType=article, longId=136177, objectId=137b1361e70a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=137b1361e70a, replyNumber=0, likeNumber=18, createdTime=2018-04-24, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=137b1361e70a, moduleTitle=Lancet Oncol:基因表达谱数据再建新功:精准判断部分滤泡性淋巴瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=137b1361e70a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278779, encodeId=a71812e8779c5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Gulf J Oncolog:眼睑淋巴样增生:一例原发性滤泡性淋巴瘤病例, objectType=article, longId=134446, objectId=af94134446d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af94134446d6, replyNumber=0, likeNumber=29, createdTime=2018-04-08, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af94134446d6, moduleTitle=Gulf J Oncolog:眼睑淋巴样增生:一例原发性滤泡性淋巴瘤病例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af94134446d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278778, encodeId=631d12e8778bb, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:结合初始和诱导后PET,建立更为准确的预测滤泡性淋巴瘤患者预后的模型, objectType=article, longId=133082, objectId=210113308256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210113308256, replyNumber=0, likeNumber=37, createdTime=2018-03-23, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210113308256, moduleTitle=Blood:结合初始和诱导后PET,建立更为准确的预测滤泡性淋巴瘤患者预后的模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=210113308256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278777, encodeId=10d012e877710, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet haemat:Voxtalisib(XL765)用于滤泡性淋巴瘤患者可获得良好的治疗效果, objectType=article, longId=132542, objectId=4f8e13254254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f8e13254254, replyNumber=0, likeNumber=35, createdTime=2018-03-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f8e13254254, moduleTitle=Lancet haemat:Voxtalisib(XL765)用于滤泡性淋巴瘤患者可获得良好的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f8e13254254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278776, encodeId=973212e8776ba, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=CLIN CANCER RES:滤泡性淋巴瘤中表达TIGIT的T细胞增多, objectType=article, longId=130882, objectId=c3ec130882e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3ec130882e6, replyNumber=0, likeNumber=33, createdTime=2018-03-01, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3ec130882e6, moduleTitle=CLIN CANCER RES:滤泡性淋巴瘤中表达TIGIT的T细胞增多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3ec130882e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278775, encodeId=f2e012e877577, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Br J Haematol:利妥昔单抗诱导治疗无症状滤泡性淋巴瘤 省钱又有效?, objectType=article, longId=130821, objectId=fe7113082182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe7113082182, replyNumber=0, likeNumber=25, createdTime=2018-03-01, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe7113082182, moduleTitle=Br J Haematol:利妥昔单抗诱导治疗无症状滤泡性淋巴瘤 省钱又有效?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe7113082182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278774, encodeId=63ea12e87748f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet haemat:R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性, objectType=article, longId=127695, objectId=d57d12e6952c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d57d12e6952c, replyNumber=0, likeNumber=34, createdTime=2018-01-27, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d57d12e6952c, moduleTitle=Lancet haemat:R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d57d12e6952c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278773, encodeId=ca7c12e8773ff, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。, objectType=article, longId=120773, objectId=59cb120e7346, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59cb120e7346, replyNumber=0, likeNumber=47, createdTime=2017-11-22, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59cb120e7346, moduleTitle=Blood:FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59cb120e7346)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
滤泡性淋巴瘤
2020-05-29
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Lancet Haematol:R-CHOP作为新确诊晚期滤泡性淋巴瘤患者一线治疗怎么样?
32
0
2018-12-14
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
JCO:利妥昔单抗时代滤泡性淋巴瘤死亡原因:队列汇总分析
37
0
2018-11-30
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:以PET-CT分层可提高滤泡性淋巴瘤患者的放射治疗效果
46
0
2018-11-19
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:基因组变异情况可用于预测滤泡性淋巴瘤患者的预后
41
0
2018-11-19
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Lancet oncol:滤泡性淋巴瘤患者经一线免疫化疗后,以PET评估缓解情况的效果优于增强CT
38
0
2018-10-11
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
N Engl J Med:晚期滤泡性淋巴瘤:利妥昔单抗+来那度胺vs利妥昔单抗+化疗
44
0
2018-09-30
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:MiR-150下调通过上调FOXP1促进滤泡性淋巴瘤向高级别淋巴瘤转化
44
0
2018-09-20
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
2018 多学科意见书:慢性淋巴细胞白血病和滤泡性淋巴瘤应用艾代拉利司治疗相关不良事件的管理
20
0
2018-09-17
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
NEJM:来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤
43
0
2018-09-13
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:十二指肠型滤泡性淋巴瘤
46
0
2018-08-23
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
J Gastroen Hepatol:无症状且肿瘤负担较低的肠滤泡性淋巴瘤的治疗方法选择
35
0
2018-08-03
回复
仁者大医
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Lancet haemat:利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险
38
0
2018-07-07
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Lancet Oncol:基因表达谱数据再建新功:精准判断部分滤泡性淋巴瘤患者的预后
18
0
2018-04-24
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Gulf J Oncolog:眼睑淋巴样增生:一例原发性滤泡性淋巴瘤病例
29
0
2018-04-08
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:结合初始和诱导后PET,建立更为准确的预测滤泡性淋巴瘤患者预后的模型
37
0
2018-03-23
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Lancet haemat:Voxtalisib(XL765)用于滤泡性淋巴瘤患者可获得良好的治疗效果
35
0
2018-03-17
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
CLIN CANCER RES:滤泡性淋巴瘤中表达TIGIT的T细胞增多
33
0
2018-03-01
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Br J Haematol:利妥昔单抗诱导治疗无症状滤泡性淋巴瘤 省钱又有效?
25
0
2018-03-01
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Lancet haemat:R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性
34
0
2018-01-27
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。
47
0
2017-11-22
回复
共73条
首页
上一页
下一页
尾页
页码:
3
/4页
20条/页
扫描二维码下载梅斯医学APP
科室
订阅+
更多科室
工具
服务